Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813694 | 0.96 | TRIM24 (0.38) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL3674258 | 0.93 | KCNH2 (0.34) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| Ethylene SCHEMBL17611952 | 0.89 | KCNH2 (0.33) | TRIM24TRIM33 | |
| SCHEMBL28272321 | 0.88 | TRIM24 (0.33) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL30447934 | 0.87 | MEN1 (0.34) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL10053527 | 0.81 | — | — | |
| SCHEMBL4693969 | 0.77 | TRIM24 (0.32) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL14721344 | 0.76 | KCNH2 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL26444546 | 0.76 | — | — | |
| SCHEMBL25833727 | 0.76 | CYP11B1 (0.31) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024255765-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023191201-A1 | NOVEL PYRAZOLE DERIVATIVES | 압타바이오 주식회사 | 2023-10-05 | — | — | WO | disclosed |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-5286860-A | Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 1994-02-15 | — | — | US | disclosed |
| EP-0552237-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5216159-A | Preferential antagonists, agonists or inverse agonists for gamma-aminobutyric acid binding sites; anxiolytic agents; anticonvulsants; treatment of sleep disorders | NEUROGEN CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1992006094-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
| EP-0207773-B1 | 7-[(Substituted)amino]-8-[(substituted)carbonyl)-methylamino]-1-oxaspiro[4.5]decanes as analgesic agents | WARNER-LAMBERT COMPANY (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4737493-A | 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents | WARNER-LAMBERT COMPANY (US) | 1988-04-12 | — | — | US | disclosed |
| EP-0207773-A2 | 7-[(Substituted)amino]-8-[(substituted)carbonyl)-methylamino]-1-oxaspiro[4.5]decanes as analgesic agents | WARNER-LAMBERT COMPANY (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4508911-A | Amine intermediates for analgesic compounds | THE UPJOHN COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| US-4438130-A | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds | THE UPJOHN COMPANY (US) | 1984-03-20 | — | — | US | disclosed |
| EP-0085811-A1 | 2-(Phenylmethylene)cycloalkylamines | THE UPJOHN COMPANY (US) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | SIRT1, ADCY5, ASIC1 | TRIM24 3262/4885TRIM33 4472/4885ALDH1A1 183/4885 |
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLB | TRIM24 1069/4885TRIM33 1294/4885ALDH1A1 2542/4885 |
| US-11739066-B2 | Method for fluoroalkylation of enamines | HNMT, PNMT, INMT | TRIM24 4446/4885TRIM33 4529/4885ALDH1A1 495/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | TRIM24 1562/4885TRIM33 4090/4885ALDH1A1 2190/4885 |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | TRIM24 1955/4885TRIM33 2396/4885ALDH1A1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.